about
Detection and delineation of oral cancer with a PARP1 targeted optical imaging agent.Immune cell screening of a nanoparticle library improves atherosclerosis therapySonophore labeled RGD: a targeted contrast agent for optoacoustic imaging.Effect of small-molecule modification on single-cell pharmacokinetics of PARP inhibitorsA Novel Technique for Generating and Observing Chemiluminescence in a Biological SettingA Comprehensive Procedure to Evaluate the In Vivo Performance of Cancer NanomedicinesHyaluronan Nanoparticles Selectively Target Plaque-Associated Macrophages and Improve Plaque Stability in AtherosclerosisEvaluation of [18F]-ATRi as PET tracer for in vivo imaging of ATR in mouse models of brain cancer.PARPi-FL--a fluorescent PARP1 inhibitor for glioblastoma imagingIn vivo imaging of GLP-1R with a targeted bimodal PET/fluorescence imaging agentSingle-cell and subcellular pharmacokinetic imaging allows insight into drug action in vivo.Harnessing the bioorthogonal inverse electron demand Diels-Alder cycloaddition for pretargeted PET imaging.A modular labeling strategy for in vivo PET and near-infrared fluorescence imaging of nanoparticle tumor targetingBioorthogonal probes for polo-like kinase 1 imaging and quantification.Radioiodinated PARP1 tracers for glioblastoma imaging.Nanoparticle-mediated measurement of target-drug binding in cancer cellsImaging therapeutic PARP inhibition in vivo through bioorthogonally developed companion imaging agentsOptical Imaging of PARP1 in Response to Radiation in Oral Squamous Cell Carcinoma.Inhibiting macrophage proliferation suppresses atherosclerotic plaque inflammationDevelopment of a clickable bimodal fluorescent/PET probe for in vivo imaging.Dual-Modality Optical/PET Imaging of PARP1 in GlioblastomaOptimization of a Pretargeted Strategy for the PET Imaging of Colorectal Carcinoma via the Modulation of Radioligand Pharmacokinetics.Microfluidic cell sorter (μFCS) for on-chip capture and analysis of single cells.PET Imaging of Tumor-Associated Macrophages with 89Zr-Labeled High-Density Lipoprotein NanoparticlesNon-invasive PET Imaging of PARP1 Expression in Glioblastoma Models.Nanoreporter PET predicts the efficacy of anti-cancer nanotherapy.Near-Infrared Intraoperative Chemiluminescence Imaging.Pretargeted PET Imaging Using a Site-Specifically Labeled Immunoconjugate.A Pretargeted Approach for the Multimodal PET/NIRF Imaging of Colorectal Cancer.Polyglucose nanoparticles with renal elimination and macrophage avidity facilitate PET imaging in ischaemic heart disease.Building Blocks for the Construction of Bioorthogonally Reactive Peptides via Solid-Phase Peptide Synthesis.The inverse electron demand Diels-Alder click reaction in radiochemistry.(18)F-Based Pretargeted PET Imaging Based on Bioorthogonal Diels-Alder Click Chemistry.A systematic comparison of clinically viable nanomedicines targeting HMG-CoA reductase in inflammatory atherosclerosis.Development of a New Folate-Derived Ga-68-Based PET Imaging Agent.Cerenkov Luminescence Imaging for Radiation Dose Calculation of a ⁹⁰Y-Labeled Gastrin-Releasing Peptide Receptor Antagonist.Investigating the Cellular Specificity in Tumors of a Surface-Converting Nanoparticle by Multimodal Imaging(18)F-labeled-bioorthogonal liposomes for in vivo targetingA pretargeted PET imaging strategy based on bioorthogonal Diels-Alder click chemistry.Molecular Imaging of PARP.
P50
Q27347956-6688364C-1881-4BCE-9291-2211F830EEFCQ28393434-2F6FAFF7-3AAB-4022-B210-50B192ECC2A0Q30359237-ACA226D9-8B64-46F0-8FEB-916588E371FCQ30575798-D1A7630C-DAA7-4F67-8326-35E874952256Q33610471-D5E89D82-F8E2-421F-AF87-8B5C84AC0C5BQ33615407-508CEDFD-1EF4-4BF9-8EF9-8B0242136DF2Q33856678-61DD73E5-3EB9-4D9B-AE54-476F03DB4254Q33925006-3256A498-FF3D-42BF-B536-F59EFDA17015Q34346449-9204E889-263B-4071-9145-D060B7262E82Q34434122-A5491711-0768-43B1-BB38-0BDA6102BC71Q34592125-ED25ADF6-A873-420C-807E-E5EE27F6A3D2Q35162177-56171A0A-82B6-4976-9DF6-E0B5D4DC8A36Q35238675-3437DF01-74EB-4E4F-993C-F6CE78F4443BQ35275729-69B8A47E-01DE-4CE0-A23F-BEB618FC42AFQ35764111-FBC310DC-AB7F-44C8-8E19-67AED1FE9C87Q35813733-163AB4E5-C17F-45E5-A395-60B08168D837Q35882189-4640FAEA-51D2-47B1-B22E-D3C402BC6528Q35903928-25DCFF7A-C48B-4E82-9C90-D90254B434ACQ35964485-840DC6D2-4178-4280-A34E-41713DC604ADQ35967818-BA7589A7-5E55-48CD-93BC-8157A10B2F70Q36172457-C10FB458-0333-4485-B9E0-F36E90770E42Q36418274-90CC3762-7542-48DB-837B-8A6EF939ED35Q36430199-9454588E-7BD2-4079-8B59-F5DA77E01884Q36533549-92E04E78-62C2-415A-83A6-2C6A01B8AFF0Q36827491-677C85AF-2FA7-42C3-B977-D2FEA244B4B9Q37024507-7C670542-83C1-48E6-863C-9175D5443976Q37333843-95E879D0-E22D-4E13-BB31-BD00AEE2165CQ37403530-D5CA8462-8F18-4CEE-9AC1-75D35696410BQ37469879-8ADE220B-104B-4154-A646-5C79A61B5B23Q37591328-B26AF771-F3EB-487D-9317-B19D3BB06D37Q37724107-44756199-8A25-46EE-A21A-A508538B0158Q38172061-CF3260B1-C192-4BAE-B796-F3A86813990DQ38556842-62DDC335-54E1-4B63-A930-0933A60FC6E9Q38682301-7A81A510-C2F5-4C10-87EE-E48642BC4FB6Q38716580-0420A36A-BF89-4AE9-B711-1D623271F890Q38891132-D4859B4D-8137-41D0-9D4F-A86F06DC2AC2Q38895968-FB474E8F-24E4-4263-A7E1-DE0BDCF468DDQ39067947-D1391D14-A430-4824-9171-7FAA0D615DC6Q39147376-ECBE55EF-B5C3-419F-B336-84AE9E1E7B1DQ39284725-D87BABE9-6CBE-4129-9578-141EDAFA1A96
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Thomas Reiner
@ast
Thomas Reiner
@en
Thomas Reiner
@es
Thomas Reiner
@nl
Thomas Reiner
@sl
type
label
Thomas Reiner
@ast
Thomas Reiner
@en
Thomas Reiner
@es
Thomas Reiner
@nl
Thomas Reiner
@sl
prefLabel
Thomas Reiner
@ast
Thomas Reiner
@en
Thomas Reiner
@es
Thomas Reiner
@nl
Thomas Reiner
@sl
P106
P21
P31
P496
0000-0002-7819-5480